10x Genomics (TXG) Free Cash Flow (2018 - 2026)

10x Genomics has disclosed Free Cash Flow across 9 years of filings, most recently posting $26.0 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $26.0 million, down 19.89% year-over-year; the trailing twelve-month figure through Mar 2026 was $123.7 million (up 178.81% YoY), and the FY2025 annual result was $130.1 million, up 2371.16% from the prior year.
• Free Cash Flow came in at $26.0 million for Q1 2026 at 10x Genomics, down from $39.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $42.5 million in Q3 2025 to a low of -$88.6 million in Q4 2022.
• The 5-year median for Free Cash Flow is $3.6 million (2024), against an average of -$2.0 million.
• Across the five-year window, Free Cash Flow plunged 3526.27% in 2022 and jumped 1447.34% in 2024, its largest moves.
• 10x Genomics' Free Cash Flow stood at -$88.6 million in 2022, then surged by 128.58% to $25.3 million in 2023, then plunged by 171.79% to -$18.2 million in 2024, then soared by 314.44% to $39.0 million in 2025, then tumbled by 33.33% to $26.0 million in 2026.
• The last three Free Cash Flow figures came in at $26.0 million (Q1 2026), $39.0 million (Q4 2025), and $42.5 million (Q3 2025), per Business Quant data.